Some targeted cancer therapies being studied in clinical trials (November 2011) (source: National Cancer Institute, USA):

Alemtuzumab (Campath)	Alitretinoin (Panretin)	Anastrozole (Arimidex)
Bevacizumab (Avastin)	Bexarotene (Targretin)	Bortezomib (Velcade)
Brentuximab vedotin (Adcetris)	Brentuximab vedotin (Adcetris)	Cetuximab (Erbitux)
Crizotinib (Xalkori)	Dasatinib (Sprycel)	Denileukin diftitox (Ontak)
Erlotinib hydrochloride (Tarceva)	Everolimus (Afinitor)	Exemestane (Aromasin)
Fulvestrant (Faslodex)	Gefitinib (Iressa)	Ibritumomab tiuxetan (Zevalin)
Imatinib mesylate (Gleevec)	Ipilimumab (Yervoy)	Lapatinib ditosylate (Tykerb)
Letrozole (Femara)	Nilotinib (Tasigna)	Ofatumumab (Arzerra)
Panitumumab (Vectibix)	Pazopanib hydrochloride (Votrient)	Pralatrexate (Folotyn)
Rituximab (Rituxan)	Romidepsin (Istodax)	Sorafenib tosylate (Nexavar)
Sunitinib malate (Sutent)	Tamoxifen	Temsirolimus (Torisel)
Toremifene (Fareston)	Tositumomab and 131I-tositumomab (Bexxar)	Trastuzumab (Herceptin)
Tretinoin (Vesanoid)	Vandetanib (Zactima)	Vemurafenib (Zelboraf)
Vorinostat (Zolinza)